E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Major Depressive Disorder |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Mental Disorders [F03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025454 |
E.1.2 | Term | Major depressive disorder, recurrent episode |
E.1.2 | System Organ Class | 100000004873 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of 2 fixed doses (5.0 mg or 2.5 mg) of MIN-117 compared with placebo in reducing the symptoms of major depression measured by the change in Montgomery-Asberg Depression Rating Scale (MADRS) total score over 6 weeks of treatment in adult patients with major depressive disorder (MDD). |
|
E.2.2 | Secondary objectives of the trial |
1. To assess the change from Baseline of 2 fixed doses (5.0 mg or 2.5 mg) of MIN-117 compared with placebo over 6 weeks of treatment on: • The symptoms of anxiety using the Hamilton Anxiety Scale (HAM-A). • The severity of illness and improvement using the Clinical Global Impression of Severity Scale and Clinical Global Impression of Improvement Scale (CGI S and CGI-I). 2. To evaluate the safety of 2 fixed doses (5.0 mg or 2.5 mg) of MIN-117 compared with placebo over 6 weeks of treatment |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patients must be able to read and understand the consent forms, complete study-related procedures, and communicate with the study staff. 2. Patients must have provided written consent to participate in the study and understand that they are free to withdraw from the study at any time. 3. Patients must be aged 18 to 65 years, inclusive, at Screening (Visit 1). 4. Meet DSM-5 criteria for diagnosis of moderate or severe major depression with anxious distress and without psychotic features at Screening based on clinical assessment and on the SCID-5 (DSM-5 codes: 296.32, 296.33; ICD-10 codes: F33.1, F33.2). Their major depressive episode must be deemed "valid" using the Massachusetts General Hospital (MGH) SAFER criteria interview administered by remote, independent raters. 5. Patients must be within a body mass index (BMI) of ≥ 18 to < 35 kg/m2 [BMI = weight (kg)/height (m)2] at Screening (Visit 1). 6. Patients have a history of at least one previous episode of depression prior to the current episode. 7. Patient must have been treated with an antidepressant administered at an adequate dose and duration in the past for the treatment of Major Depression. An adequate treatment is defined as an antidepressant treatment for at least 4 weeks at at least the minimum therapeutic dose, for any particular antidepressant. 8. Current major depressive episode of at least 4 weeks in duration. 9. At Screening (Visit 1) and Baseline (Visit 2), patients must have a score ≥ 40 on the patient rated IDS SR30. 10. At Screening (Visit 1) and Baseline (Visit 2), patients must have a score ≥ 18 on HAM-A. 11. At Screening (Visit 1) and Baseline (Visit 2), patients must have a score ≥ 4 on the investigator-rated CGI-S. 12. Patients must be in good general health prior to study participation with no clinically relevant abnormalities as assessed by the investigator and determined by: medical history, physical examination, vital signs, blood chemistry, hematology, urinalysis, and electrocardiogram (ECG). 13. If female, the patient must: • be post-menopausal, or • have had a hysterectomy or tubal ligation or be otherwise incapable of pregnancy, or • must agree to consistent use of 2 methods of contraception for the duration of the study and until 90 days after the last dose of study medication. One of which must be a highly effective method defined as one that results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly. The following highly effective contraception methods acceptable for this study are hormonal contraception (oral or parenteral hormonal contraceptive) or placement of an intrauterine device. The following methods can be used as a second form of contraception during the study: Barrier methods for female patients include their partner’s use of a condom or the subject’s use of an occlusive cap (diaphragm or cervical/ vault caps) with spermicidal foam, gel, film, cream or suppository. 14. If male with partner of childbearing potential, must be willing to use one barrier method of contraception with his partner throughout the study (a condom or his partner’s use of an occlusive cap [diaphragm or cervical/ vault caps]). His partner must also be using a highly effective method of birth control defined as one that results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as sterilization, implants, injectables, combined oral contraceptives, and intrauterine devices for up to 90 days after the last dose of study treatment. The patient must agree to inform the investigator if his partner becomes pregnant during the course of the study. 15. Male patients who have been sterilized or have partners of non-childbearing potential (including homosexual men) are required to use one barrier method of contraception. This is to prevent unintended exposure of the partner to the study drug via seminal fluid (for male subjects, this must be a condom or their partner's use of an occlusive cap [diaphragm or cervical/vault caps]. 16. Female patients of childbearing potential must have a negative serum pregnancy test at Screening (Visit 1) and negative serum and urine pregnancy test at Baseline (Visit 2) |
|
E.4 | Principal exclusion criteria |
1. A DSM-5 diagnosis of current (active): panic disorder, obsessive compulsive disorder (OCD), post traumatic stress disorder (PTSD), anorexia nervosa, or bulimia nervosa. 2. History or current diagnosis of a psychotic disorder, bipolar disorder, mental retardation, or borderline personality disorders, mood disorder with postpartum onset, somatoform disorders, fibromyalgia, or idiopathic medical conditions. 3. At significant clinical risk for suicidal or violent behavior. 4. Potential patient who demonstrate a greater than 25% decrease in depressive symptoms as reflected by the IDS-SR30 total score from Screening visit to Baseline visit. 5. Active cardiovascular disease (including but not limited to: atrial fibrillation or flutter, second and third-degree atrioventricular heart block, resting supraventricular tachycardia >100 beats per minute, unstable ischemic heart disease, valvular abnormality, sick sinus syndrome or other condition requiring pacemaker) or diastolic blood pressure > 105 mmHg. 6. Any serious, untreated, or unstable illnesses, such as: liver or renal insufficiency. 7. Any significant pulmonary, endocrine, or metabolic disturbances. 8. Documented disease of the central nervous system that could interfere with the study assessments (including but not limited to: stroke, tumor, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, seizure disorder requiring current anti-convulsants, traumatic brain injury or trauma, and neurosyphilis. 9. Hypothyroidism or hyperthyroidism, unless stabilized by appropriate medication for at least 3 months prior to Screening (a normal thyroid-stimulating hormone [TSH] is required prior to randomization at Baseline). 10. Any medical condition that can potentially alter oral enteral absorption (e.g., gastrectomy), metabolism (e.g., liver failure), or excretion (e.g., renal failure) of the study drug. 11. History of alcohol or substance use disorders (except nicotine and caffeine) meeting DSM-5 criteria within 1-year prior to Screening visit. 12. Positive alcohol and urine drug screen for opiates, cocaine, barbiturates, tetrahydrocannabinol, methadone, and amphetamine/methamphetamine at Screening and randomization. 13. QTcF interval at Screening or Baseline greater than 450 msec for males and 470 msec for females. 14. Positive alcohol and urine drug screen for opiates, cocaine, barbiturates, tetrahydrocannabinol, methadone, tricyclic antidepressants, benzodiazepines and amphetamine/methamphetamine at Screening or Baseline. Patients with positive testing due to prescribed benzodiazepines, tricyclic antidepressants, barbiturates, or opiates at Screening are accepted but must test negative at Baseline (Visit 2). 15. Male patients who have pregnant partners. 16. Female patients who are breastfeeding. 17. Received an experimental drug or used an experimental medical device within 60 days before the planned start of treatment (Day 1) or have participated in 2 or more clinical trials in the previous 2 years. 18. QTcF interval at Screening or Baseline greater than 450 msec for males and 470 msec for females. 19. Patients requiring treatment with drugs likely to prolong QT. 20. Patients with known hypersensitivity to MIN-117 or placebo or their excipients (refer to Section 13.1 of the protocol) 21. Positive hepatitis B surface antigen, or hepatitis C antibody or Human Immunodeficiency Virus (HIV) 1 and 2 antibodies at Screening. 22. Employees of the investigator or study center, when the employee has direct involvement in the proposed study or other studies under the direction of that investigator or study center; also family members of the employee or the investigator. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Mean change in the MADRS total score from Baseline to Week 6. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The mean change from Baseline to Week 6 in MADRS total score |
|
E.5.2 | Secondary end point(s) |
1) Change in symptoms of anxiety using the Hamilton Anxiety scale (HAM-A) 2) Changes in the severity of illness and improvement using the Clinical Global Impression of Severity Scale (CGI-S) and Clinical Global Impression of Improvement Scale (CGI-I).
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1) mean change from Baseline to Week 6 in HAM-A total score 2) mean changes in CGI-S and CGI-I from Baseline to Week 6 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 19 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Bulgaria |
Finland |
Poland |
Ukraine |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 2 |